Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:

Platanias Receives 2013 Milstein Award

Platanias  Receives 2013 Milstein Award
Leonidas Platanias, MD, PhD, Deputy Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, has been selected to receive the 2013 Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research. He received the prize on September 29 at the annual meeting of the International Cytokine and Interferon Society in San Francisco.
The Milstein Award, which represents the pinnacle of scientific achievement in cytokine and interferon research, is bestowed upon a leading biomedical research scientist who has made outstanding contributions to interferon and cytokine research, either in a basic or applied field. Many Laureates have made seminal advancements that have enabled the successful treatment of disease or have the potential to lead to significant health benefits.
The Milstein Award was established in 1988. Since that time, it has been widely recognized that interferons and the larger class of cytokines play critical roles in the development and progression of many major diseases including cancer, viral diseases such as hepatitis and influenza, and autoimmune disorders like multiple sclerosis and lupus. Past Milstein Award Laureates include Tadatsugo Taniguchi, PhD, Thomas Maniatis, PhD, and James Darnell, Jr., MD.
Platanias, the Jesse, Sara, Andrew, Abigail, Benjamin and Elizabeth Lurie Professor of Oncology, and Professor of Medicine at Northwestern University Feinberg School of Medicine, has focused his research efforts on the field of signal transduction in cancer for over 20 years; studying the mechanisms of signaling for cytokines and other ligands in malignant cells. In recent years, he has performed extensive work on the mechanisms of interferon signaling in malignancies and of arsenic trioxide signaling in leukemia. In addition, his laboratory has defined kinase elements as targets for the development of innovative therapeutic approaches in myeloid leukemias. 

(Last updated on October 1, 2013 )